MedTrace Logo

NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing

NCT05825625 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2025-05-23

No results posted yet for this study

Summary

Prospective, non-randomized, open-label, single-arm phase II trial to investigate the feasibility and efficacy of combining chemotherapy with tiragolumab and atezolizumab as neoadjuvant and adjuvant treatment for surgical NSCLC patients.

Conditions

Interventions

DRUG

Atezolizumab

Atezolizumab 1,200 mg by IV infusion Q3W.

DRUG

Tiragolumab

Tiragolumab by IV infusion Q3W.

Sponsors & Collaborators

  • Thoraxklinik-Heidelberg gGmbH

    collaborator OTHER

  • Roche Pharma AG

    collaborator INDUSTRY

  • Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

    lead OTHER

Principal Investigators

  • Salah-Eddin Al-Batran, Prof. Dr. · Institut für Klinische Krebsforschung IKF GmbH

  • Florian Eichhorn, Dr. · Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-26
Primary Completion
2026-12-01
Completion
2027-06-01

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05825625 on ClinicalTrials.gov